LOGIN  |  REGISTER
Chimerix

Premier Health Announces CEO Departure

March 27, 2025 | Last Trade: C$0.05 0.005 12.50

MONTRÉAL, March 27, 2025 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces that Martin Legault has resigned from his role as President and Chief Executive Officer of the Corporation, as well as from his position on the Board of Directors, effective as of March 27, 2025. The Corporation thanks Mr. Legault for his 22 years of service and leadership.

Guy Daoust, the Chief Financial Officer of the Corporation, has been appointed as Interim President and Chief Executive Officer of the Corporation effective as of March 27, 2025, while the Board of Directors evaluates potential candidates to fill the position permanently.

The Corporation will apply for a waiver from Section 5.9 of Policy 3.1 of the TSX Venture Exchange to allow Mr. Daoust to concurrently act as Interim Chief Executive Officer and Chief Financial Officer.

About Premier Health

Premier Health is a leading Canadian Healthtech company that provides a comprehensive range of outsourced services solutions for healthcare needs to governments, corporations, and individuals. Premier Health uses its proprietary LiPHe platform to lead the healthcare services sector digital transformation to provide patients with faster, cheaper and more accessible care services.

For Further Information Please Contact:

Mr. Jean-Robert Pronovost
Vice-President, Corporate Development
Premier Health of America Inc.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
Phone: 1 800 231 9916

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION:

This press release contains forward-looking information based on current expectations. Statements about the date of trading of the Corporation’s common shares on the Exchange and final regulatory approvals, among others, are forward-looking information. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. The Corporation assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. These factors and others are more fully discussed in the filings of the Corporation with Canadian securities regulatory authorities available at www.sedarplus.ca .


Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page